ALGN — Align Technology, Inc.

Is ALGN overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Medical Instruments & Supplies

Oversold As of August 19, 2026

Align Technology, Inc. (ALGN) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Medical Instruments & Supplies) last closed at $163.04. The rating moved from Overbought to Oversold on August 18, 2026.

See all oversold Healthcare stocks →

AI analysis

Align Technology, Inc. (ALGN) benefits from a leading global brand in clear aligners and a growing digital ecosystem that supports recurring revenue and long-term margin improvement. Near-term performance hinges on elective-procedure demand and execution on international expansion and software adoption; absent major macro shocks, earnings commentary and product adoption will drive direction in the coming weeks. Key downside risks include competitive pricing pressure, macro-driven procedure slowdowns, and execution-related supply or regulatory setbacks.

Key factors

  • Leading market position in clear aligners via the Invisalign brand and wide provider adoption, supporting pricing power and installed base advantages
  • Strong digital ecosystem (iTero scanners, treatment-planning software) that creates recurring hardware/software services revenue and competitive differentiation
  • Historical revenue growth and margin expansion potential from higher mix of digital services, consumables, and international penetration
  • Operational leverage and potential for improved margins as unit volume recovers and fixed-cost absorption improves
  • Exposure to elective-procedure tailwinds as consumer health spending normalizes, with potential upside from expansion in adult orthodontics and emerging markets
  • Macro and market environment in the last four hours showed balanced risk appetite with no major macro shocks, leaving company-specific execution and earnings commentary as primary near-term drivers

Risks

  • Demand sensitivity to consumer discretionary spending and macro/interest-rate driven pullbacks in elective dental procedures
  • Intensifying competition from direct-to-consumer entrants, dental chains, and other clear-aligner manufacturers that could pressure share and pricing
  • Execution risk on scaling international markets, supply-chain constraints, or slower-than-expected adoption of iTero and software offerings
  • Regulatory, reimbursement, or litigation risks tied to dental/medical device claims and distributor relationships
  • Foreign-exchange exposure and geographic concentration risks as international growth comprises an increasing share of revenue
  • Limited real-time social/research sentiment data in the provided window, increasing short-term informational uncertainty

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for ALGN — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.